使用地尼白介素-妥索罗汀进行的抑制细胞清除免疫疗法是一种有效的针对结核病的宿主导向疗法。
Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.
作者信息
Gupta Shashank, Cheung Laurene, Pokkali Supriya, Winglee Kathryn, Guo Haidan, Murphy John R, Bishai William R
机构信息
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
National Emerging Infectious Diseases Laboratories Institute, Boston University, Massachusetts.
出版信息
J Infect Dis. 2017 Jun 15;215(12):1883-1887. doi: 10.1093/infdis/jix208.
Abstract
Host-directed therapies that augment host immune effector mechanisms may serve as important adjunctive therapies for tuberculosis treatment. We evaluated the activity of denileukin diftitox in an acute mouse model of tuberculosis (TB) infection and analyzed the cellular composition and bacterial burden in lungs and spleens. These in vivo studies show that denileukin diftitox potentiates standard TB treatment in the mouse model, an effect which may be due to depletion of T-regulatory and myeloid-derived suppressor cells during TB infection. Our results indicate that denileukin diftitox and other suppressor cell-depleting therapies may be useful adjunctive, host-directed therapies for TB.
摘要
增强宿主免疫效应机制的宿主导向疗法可能成为结核病治疗的重要辅助疗法。我们在急性小鼠结核病感染模型中评估了地尼白介素（denileukin diftitox）的活性，并分析了肺和脾中的细胞组成及细菌负荷。这些体内研究表明，地尼白介素在小鼠模型中可增强标准结核病治疗效果，这一效应可能归因于结核病感染期间调节性T细胞和髓源性抑制细胞的耗竭。我们的结果表明，地尼白介素及其他抑制细胞耗竭疗法可能是有用的辅助性宿主导向结核病治疗方法。
相似文献
1
Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.
J Infect Dis. 2017 Jun 15;215(12):1883-1887. doi: 10.1093/infdis/jix208.
2
Effective Host-Directed Therapy for Tuberculosis by Depletion of Myeloid-Derived Suppressor Cells and Related Cells Using a Diphtheria Toxin Fusion Protein.
J Infect Dis. 2021 Dec 1;224(11):1962-1972. doi: 10.1093/infdis/jiab235.
3
Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Vet Immunol Immunopathol. 2012 Jan 15;145(1-2):233-40. doi: 10.1016/j.vetimm.2011.11.009. Epub 2011 Nov 25.
4
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
Blood. 2007 Nov 1;110(9):3192-201. doi: 10.1182/blood-2007-06-094615. Epub 2007 Jul 6.
5
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
Gynecol Oncol. 2024 Dec;191:74-79. doi: 10.1016/j.ygyno.2024.09.019. Epub 2024 Oct 2.
6
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
J Immunother. 2005 Nov-Dec;28(6):582-92. doi: 10.1097/01.cji.0000175468.19742.10.
7
An evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma.
Expert Opin Biol Ther. 2025 Jul;25(7):687-694. doi: 10.1080/14712598.2025.2517853. Epub 2025 Jun 14.
8
Denileukin diftitox.
Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. doi: 10.2165/00128071-200001010-00008.
9
Xpert MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.
Cochrane Database Syst Rev. 2018 Aug 27;8(8):CD012768. doi: 10.1002/14651858.CD012768.pub2.
10
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
引用本文的文献
1
The Research Progress in Immunotherapy of Tuberculosis.
Front Cell Infect Microbiol. 2021 Nov 15;11:763591. doi: 10.3389/fcimb.2021.763591. eCollection 2021.
2
Immunotherapy With 5, 15-DPP Mediates Macrophage M1 Polarization and Modulates Subsequent Infectivity in rBCG30 Immunized Mice.
Front Immunol. 2021 Oct 29;12:706727. doi: 10.3389/fimmu.2021.706727. eCollection 2021.
3
Effective Host-Directed Therapy for Tuberculosis by Depletion of Myeloid-Derived Suppressor Cells and Related Cells Using a Diphtheria Toxin Fusion Protein.
J Infect Dis. 2021 Dec 1;224(11):1962-1972. doi: 10.1093/infdis/jiab235.
4
Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis.
Front Immunol. 2021 Apr 19;12:660916. doi: 10.3389/fimmu.2021.660916. eCollection 2021.
5
Host-directed therapy to combat mycobacterial infections.
Immunol Rev. 2021 May;301(1):62-83. doi: 10.1111/imr.12951. Epub 2021 Feb 9.
6
The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review.
Antibiotics (Basel). 2021 Jan 19;10(1):91. doi: 10.3390/antibiotics10010091.
7
Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors.
J Leukoc Biol. 2021 Jul;110(1):177-186. doi: 10.1002/JLB.4A0720-409RR. Epub 2020 Nov 6.
8
Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
Front Immunol. 2020 Jul 21;11:1553. doi: 10.3389/fimmu.2020.01553. eCollection 2020.
9
Target the Host, Kill the Bug; Targeting Host Respiratory Immunosuppressive Responses as a Novel Strategy to Improve Bacterial Clearance During Lung Infection.
Front Immunol. 2020 Apr 30;11:767. doi: 10.3389/fimmu.2020.00767. eCollection 2020.
10
Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.
J Clin Invest. 2020 Jun 1;130(6):2789-2799. doi: 10.1172/JCI136288.
本文引用的文献
1
Versatile myeloid cell subsets contribute to tuberculosis-associated inflammation.
Eur J Immunol. 2015 Aug;45(8):2191-202. doi: 10.1002/eji.201545493.
2
Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis.
Am J Respir Crit Care Med. 2014 Nov 1;190(9):1053-66. doi: 10.1164/rccm.201405-0828OC.
3
Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.
Am J Respir Crit Care Med. 2013 Sep 1;188(5):600-7. doi: 10.1164/rccm.201304-0650OC.
4
Pathogen-specific Treg cells expand early during mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12.
Immunity. 2013 Jun 27;38(6):1261-70. doi: 10.1016/j.immuni.2013.06.003. Epub 2013 Jun 20.
5
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.
Leuk Lymphoma. 2013 Jul;54(7):1373-9. doi: 10.3109/10428194.2012.742521. Epub 2013 Jan 29.
6
Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas.
J Invest Dermatol. 2012 Apr;132(4):1239-46. doi: 10.1038/jid.2011.416. Epub 2011 Dec 22.
7
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.
BMC Cancer. 2011 Dec 13;11:515. doi: 10.1186/1471-2407-11-515.
8
Therapeutic enhancement of protective immunity during experimental leishmaniasis.
PLoS Negl Trop Dis. 2011 Sep;5(9):e1316. doi: 10.1371/journal.pntd.0001316. Epub 2011 Sep 6.
9
A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).
J Immunother. 2010 Sep;33(7):716-22. doi: 10.1097/CJI.0b013e3181e4752e.
10
Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis.
J Exp Med. 2007 Sep 3;204(9):2159-69. doi: 10.1084/jem.20062105. Epub 2007 Aug 20.
Zotero 插件